Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > FDA accepted Intercept’s NDA for NASH!

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jan 24, 2023 4:27pm

146 Views

Post# 35243346

RE:RE:RE:RE:RE:RE:FDA accepted Intercept’s NDA for NASH!

It is still breathing and has a pulse. But it is very quiet. That might mean good news is developing (NASH partnership, cancer developments), bad news is developing (cancer is being shelved, no interest in NASH) or both. Obviously, there are other possibilities too. One thing we have heard is that the interest in NASH really has picked up considerably since MDGL reported their positive results. My sense is things will remain pretty quiet until they have something to announce. They will have to announce earnings, however, so we will get some sort of update at that time, which will likely be mid-late February.